Federal push to fast-track psychedelics
- A federal executive order directed the FDA to give expedited consideration to certain psychedelic drugs. - The order explicitly names ibogaine as a controversial candidate for accelerated review. - States, veterans' advocates, and researchers are divided while some states propose research initiatives like Louisiana's bill ( ).
President Donald Trump ordered federal agencies to speed the path for some psychedelic drugs, putting the Food and Drug Administration on the spot to move faster. (federalregister.gov) The executive order, signed April 18 and published in the Federal Register on April 22, says the Food and Drug Administration should prioritize psychedelic drugs that already have Breakthrough Therapy designation and fit the agency’s National Priority Voucher program. It also says the Department of Health and Human Services should direct $50 million to match state spending on psychedelic research. (federalregister.gov, time.com) The order names ibogaine, a psychoactive compound from a West African shrub, as a drug that “show[s] potential” for patients whose illness persists after standard treatment. CNBC reported FDA Commissioner Marty Makary said the agency would issue national priority vouchers for three psychedelics and was taking steps toward the first human ibogaine trials in the United States. (federalregister.gov, cnbc.com) Psychedelics are drugs that alter perception and mood, and most of the best-known ones remain Schedule I substances under federal law. The new order does not approve any drug or change the evidence the Food and Drug Administration must require on safety and effectiveness before a drug can be sold. (time.com, federalregister.gov) The timing follows a bruising stretch for the field. In June 2024, the Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted 2-9 against finding MDMA effective for post-traumatic stress disorder and 10-1 against saying its benefits outweighed its risks; the agency later declined the application. (fda.gov, psychiatrictimes.com) At the same time, some companies still have drugs in the pipeline. Time reported that Compass Pathways’ synthetic psilocybin treatment has Breakthrough Therapy designation for treatment-resistant depression, one of the categories that could benefit from faster federal review. (time.com, psychiatrictimes.com) Veterans’ advocates helped drive the White House event. CNBC reported former Navy SEAL Marcus Luttrell told Trump that ibogaine “absolutely changed my life for the better,” while Health and Human Services Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan stood with administration officials during the signing. (cnbc.com) Researchers and clinicians are not aligned on ibogaine. A peer-reviewed review in the National Library of Medicine says ibogaine has been linked to deaths and dangerous heart-rhythm problems, including QT prolongation and torsades de pointes, even as small studies have explored it for opioid withdrawal and addiction. (pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov) States are moving on a parallel track. In Louisiana, Senate Bill 43 by Sen. Patrick McMath passed the Senate 37-0 on April 15 and would create a state psychedelic-assisted therapy program inside the Louisiana Department of Health. (legis.la.gov, kplctv.com) The next test is not the ceremony but the paperwork: whether the Food and Drug Administration uses the new priority tools, whether states put up matching money, and whether any sponsor can produce data strong enough to survive the same review that blocked MDMA in 2024. (federalregister.gov, time.com, fda.gov)
